Denteric is developing therapies to treat Porphyromonas gingivalis related diseases. Our initial focus is on severe periodontal disease. Our vaccine therapy aims to generate antibodies that neutralise the proteolytic toxins of the bacteria that cause periodontal disease and inflammation. We are currently in phase I clinical trials.
| Website | http://www.denteric.com |
| Employees | 10 (6 on RocketReach) |
| Founded | 2019 |
| Address | 31 Queen St, Melbourne, Victoria 3000, AU |
| Industry | Biotechnology Research, Drug Discovery, Biotechnology |
| Keywords | Periodontitis Treatment, Gingivitis Treatment, Gum Disease Treatment, Oral Health, Dental Health, Bacterial Infections, Immunotherapy, Oral Microbiome, Therapeutic Antibodies, Disease Prevention, Infectious Disease, Biologics, Novel Therapies |
| Competitors | Align Technology, OrthoFX, Invisalign Orthodontist US, ClearCorrect, SmileDirectClub, Snap-On Smile, 3M, Patterson Dental, Henry Schein, Cerec +29 more (view full list) |
Looking for a particular Denteric employee's phone or email?
Denteric Questions
Larisa Chisholm is the COO of Denteric.
6 people are employed at Denteric.
Denteric is based in Melbourne, Victoria.
Top Denteric Employees
-
Larisa Chisholm
Chief Operating Officer at Denteric
Melbourne, VIC, AU22 -
Sean McLoughlin
Chief Executive Officer at Denteric
Philadelphia, PA, US11 -
15+
-
Allister Loughran
Senior Translational Scientist at Denteric
Melbourne, VIC, AU23 -
Michal Pasternak
Director, Early Drug Development at Denteric
Melbourne, VIC, AU11 -
2
G2Crowd Trusted
300K+
Plugin Users
